CardiNor – Secretoneurin ELISA

CardiNor AS is a Norwegian diagnostic company founded in June 2015 to handle the commercialisation of secretoneurin (SN), with the purpose of fighting the Heart Failure (HF) epidemic by leveraging the patented blood biomarker secretoneurin (SN). CardiNor is located in Oslo with an R&D department in Bodø, in northern Norway.

SN addresses a medical unmet need by providing prognostic insights and risk stratification of patients with life threatening arrhythmias to aid in patient selection for ICD treatment (implantable cardioverter-defibrillator), and other cardiovascular diseases (CVD).

CardiNor received CE-IVD registration of its Secretoneurin ELISA assay end of 2021.

CardiNor Secretoneurin ELISA

CardiNor have developed a secretoneurin ELISA (Enzyme-linked immunosorbent assay) based on two secretoneurin-specific monoclonal antibodies (MABs) from sheep. One MAB is biotinylated and the second is HRP-conjugated. The CardiNor Secretoneurin ELISA kit includes 6 calibrators and high and low controls.

What is secretoneurin (SN)?

Secretoneurin is a 33-amino acid neuropeptide and the biological active fragment of secretogranin II (SgII), a protein in the granin family. SN is produced by neuroendocrine and heart muscle cells by endoproteolytic cleavage of SgII. Secretoneurin is detectable in the blood stream.

SN appears as a strong and independent predictor of mortality in several patient cohorts, including patients with ventricular arrhythmia, acute heart failure, patients with acute respiratory failure with CVD, and severe sepsis. Importantly, secretoneurin seems to provide prognostic information independent of currently used cardiac biomarkers and one could therefore envision secretoneurin as part of a biomarker panel together with cardiac troponin and BNP.

SN is thus addressing a vast and untapped market potential for CVD patient prognosis, risk stratification and monitoring, complementary to BNP/NT-proBNP and cardiac troponins.

In the paper “Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial” many data are shown on the usefulness of using NS as a prognosis for cases of heart failure.

If you have any questions or queries, you can contact us here: